Assessment of Fibroblast Growth Factor 23 as an early predictor in Chronic Kidney Diseases Patients

Abstract

Fibroblast growth factor -23(FGF23)  was initially identified as the causative factor of autosomal dominant hypophosphatemic rickets ,further studies confirmed that FGF 23 is predominantly expressed in the osteocytes and osteoblasts of bone . (FGF23) is an endocrine hormone that regulates phosphate and vitamin D homeostasis. FGF23 is synthesized and secreted by bone cells, mainly osteocytes and plays a role as a phosphatonin (a phosphate regulating protein). FGF23 inhibits phosphate reabsorption in the renal tubule and promotes phosphaturia by down-regulating sodium-phosphate co-transporters. As kidney function decreases in chronic kidney disease (CKD) patients, FGF23 increases progressively in order to regulate phosphate homeostasis .This study will include two  groups : group 1 patient with chronic kidney disease (CKD) in different CKD stages according to estimated  glomerular filtration rate   (eGFR) .group 2 healthy persons with no chronic kidney disease. Both groups investigated  for (creatinine, phosphorus, total and ionized calcium, albumin ,PTH hormone,FGF23 and eGFR  was calculated).